SYDNEY, AUSTRALIA – November 22, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the INSIGHT-003 trial has been expanded to four sites across Germany including the University Clinic of Ruhr Universität Bochum and the Lung Clinic Cologne-Merheim. This site expansion will support faster enrolment in this cost-efficient, investigator-initiated study evaluating eftilagimod alpha (efti) in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and doublet chemotherapy for first line treatment of non-squamous non-small cell lung cancer (NSCLC).
The strength of the early clinical data in this first-in-man triple combination study led to its increase to 50 patients. The extension opened in mid-2023 and 29 patients have been enrolled to date. With the addition of the new sites, the trial is expected to complete recruitment in 1H CY2024.
For more information, download the attached PDF.
Download this document